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ABSTRACT 
Antimalarial piperaquine (PQ) is currently used as a partner drug with dihydroartemisinin 
(DHA), exhibiting high cure rates (>95%) for P. falciparum. Despite its raising usage        
worldwide with DHA, PQ is synthetically developed outside of big pharma pipelines. Thus, 
there is potentially some scientific gap in the information regarding disposition of the drug not 
being systematically established. This thesis comprised studies on bioanalysis- (Paper I), 
CYP3A4/5 inhibitory potential- (Paper II), protein binding- (Paper III) and pharmacokinetics 
(PK) of piperaquine and its metabolites (Paper IV) with intention of filling these scientific gaps. 
PQ in earlier studies metabolized to two main urinary metabolites, M1 which is a carboxylic 
acid cleavage product and M2, the mono N-oxide of PQ. PQ and M2 were found as potent 
CYP3A inhibitors whereby M2 showed greater inhibition in vitro. Simulation of PQ inhibitory 
effect, predicted the drug-drug interaction (DDI) between PQ and co-administered midazolam in 
healthy subjects during antimalarial PQ treatment.  Bioanalytical method was developed using a 
highly sensitive analytical instrument, LC-MS/MS to determine PQ and its metabolites in   
human plasma. The simultaneous quantitation method of PQ and metabolites was developed 
and validated for the first time based on the FDA guidelines. The method was applied for PK 
studies of PQ and metabolites after oral administration of single and escalating dose regimen of 
Artekin® (DHA-PQ) in Vietnamese healthy subjects. PQ exhibited dose- and time independent 
kinetics. M2 was found to be circulating metabolites in plasma while M1 was hardly detected. 
Plasma protein binding of PQ and its metabolites were studied in vitro whereby PQ was      
extensively bound to plasma proteins with higher affinity towards AGP protein than to the 
albumin while metabolites, exhibited a much lower degree of binding. Unbound fractions of PQ 
and metabolites were successfully determined in human plasma by ultrafiltration. Generally, the 
utmost contribution of this thesis is the application of bioanalysis method to quantitate the   
antimalarial PQ and its metabolites for pharmacokinetics including CYPs- and protein binding 
studies. As other antimalarials, PQ nowadays should be carefully evaluated for its treatment 
benefit and risk potential considering the challenge of increasing antimalarial resistance.     
Furthermore, DHA-PQ is suggested for mass-drug-administration (MDA) to eliminate malaria 
in Sub-Saharan Africa.  
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